Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, November 29, 2014
 
Register | Sign in
Home Page > Videos > BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Tumor Extracellular Vesicles
  Videos

Return

BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Tumor Extracellular Vesicles
Massachusetts General Hospital

Development of biofluid-based molecular diagnostic tests for cancer is an important step towards tumor characterization and real-time monitoring in a minimally invasive fashion. Extracellular vesicles (EVs) are released from tumor cells into body fluids and can provide a powerful platform for tumor biomarkers since they carry tumor proteins and nucleic acids. BEAMing (beads, emulsion, amplification, magnetics) PCR is substantially more sensitive than many other assays for detecting single nucleotide mutations when there is a significant background of wild-type sequences. Picodroplet digital PCR developed by RainDance Technologies is another highly sensitive technology that can be used to quantify rare mutations in a high wild type background. Here, we describe a novel approach that uses BEAMing droplet RT-PCR, as well picodroplet digital RT-PCR, to interrogate mRNA sequences contained within EVs from serum and cerebrospinal fluid (EV-BEAMing). Using both assays, we were able to reliably detect and quantify mutant and wild-type IDH1 transcripts in cerebrospinal fluid of patients with gliomas. EV-BEAMing and picodroplet dPCR are valuable new tools for cancer diagnostics which can be applied to a variety of biofluids and neoplasms.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Gene Therapy Provides Safe, Long-Term Relief for Patients with Severe Hemophilia B
Gene therapy pioneered by St. Jude Children’s Research Hospital, University College London and the Royal Free Hospital provides men with hemophilia B reliable relief from the bleeding disorder.
Protein Predicts Response To New Immunotherapy Drug
Trial shows that response to treatment may be predicted by the presence of an immune-suppressing protein in non-cancerous immune cells.
NIAID/GSK Experimental Ebola Vaccine Appears Safe, Prompts Immune Response
Results from NIH Phase 1 clinical trial support accelerated development of candidate vaccine.
Researchers Develop Efficient Method to Produce Nanoporous Metals
New technique to manufacture nanoporous metals is cheap and can be done over many scales.
Turkeys may be Lifesavers
Antibiotic to target staph infections, strep, comes from good bacteria in turkeys.
A Hybrid Vehicle That Delivers DNA
University at Buffalo researchers are developing new technology to improve DNA vaccines. The new transport system for DNA vaccines could help treat HIV, malaria, HPV and other major illnesses.
Big Data Set To Make A Big Difference In Childhood Cancer Treatment
UTS researchers are working with the Kids Research Institute to visualise large quantities of patient data to better diagnose and treat childhood cancer patients.
Two Studies Identify A Detectable, Pre-Cancerous State In The Blood
Findings pave way for new lines of cancer research focused on detection and prevention.
A Link between DNA Transcription and Disease-Causing Expansions Which Lead to Hereditary Disorders
A Tufts University study explores the relationship between transcription and the expansions of DNA repeats.
Did You Hear The One About The Two Businessmen On A Plane?
EquipNet’s vision ‘to revolutionize the way companies manage their surplus assets’ was first conceived at 30,000 feet somewhere between Chicago and Boston in 1999. Here we learn more about the company's first 15 years.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv